Compare Enphase Energy Inc (ENPH) vs Maravai LifeSciences Holdings Inc. Class A Common Stock (MRVI) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Enphase Energy Inc vs Maravai LifeSciences Holdings Inc. Class A Common Stock — how do they compare? Enphase Energy Inc trades at $29.06 (market cap $4.23B), while Maravai LifeSciences Holdings Inc. Class A Common Stock trades at $6.56 (market cap $972.90M). The key difference: Enphase Energy Inc is far larger — about 4.3× Maravai LifeSciences Holdings Inc. Class A Common Stock's market cap, and Maravai LifeSciences Holdings Inc. Class A Common Stock is trading nearer its 52-week high, Enphase Energy Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Enphase Energy Inc for 72 Days and Maravai LifeSciences Holdings Inc. Class A Common Stock for 0 Days on average.
| ENPH | MRVI | |
|---|---|---|
Market Cap | $4.23B | $972.90M |
Volume | 4,755,897 | 4,325,710 |
Sector | Energy | Health |
52-Week High | $72.33 | $9.00 |
52-Week Low | $26.12 | $2.83 |
Typical Hold Time | 72 Days | 0 Days |
Enterprise Value | $3.88B | $1.08B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Enphase Energy (ENPH) trades at $29.35, down 6.8% in the last session, reflecting recent volatility amid broader solar sector pressures. The stock shows a bearish technical signal with key support at $29. Valuation ratios like a P/E of 31.71 and P/S of 3.22 suggest a premium, while recent quarters saw mixed earnings with two misses. Positive developments include utility approvals for its IQ Meter Collar and advancements in solid-state transformer technology for AI data centers.
The outlook is cautious; while analyst consensus targets $43.18 implying upside, high borrowing costs and competitive risks weigh on solar stocks. Revenue declined from 2023's $2.3B to $1.47B in 2025, though net margins improved. Investors should balance growth potential in energy tech against execution risks and market sentiment shifts.
Maravai LifeSciences (MRVI) trades at $6.53, down 7.51% in the last session amid mixed signals. The stock shows improving fundamentals with Q2 2026 revenue growth of 9% and three consecutive earnings beats, though it remains unprofitable with a -37.07% net margin. Technical analysis indicates neutral positioning with key support at $6 and resistance at $7. Recent news highlights patent expansions in China and institutional accumulation.
The outlook remains cautiously optimistic with analyst consensus pointing to 7% upside potential to the $7.00 price target. Key opportunities include margin expansion and RNA technology leadership, while risks center on persistent cash burn and competitive pressures in life sciences. The stock offers speculative growth potential for risk-tolerant investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Enphase Energy Inc
Enphase Energy is a global energy technology company. The company delivers smart, easy-to-use solutions that manage solar generation, storage, and communication on one platform. The company's microinverter technology primarily serves the rooftop solar market and produces a fully integrated solar-plus-storage solution. Geographically, it derives a majority of revenue from the United States.
Read more on ENPH →About Maravai LifeSciences Holdings Inc. Class A Common Stock
Maravai LifeSciences Holdings Inc. is a life sciences company supporting drug therapy, diagnostic, and vaccine development through four operating brands: TriLink BioTechnologies (nucleic acid and mRNA synthesis), Cygnus Technologies (biologics safety testing), Glen Research (oligonucleotide synthesis materials), and Alphazyme (enzyme manufacturing). It serves biotech and biopharma customers from discovery through commercial manufacturing.
Read more on MRVI →
